Introduction and Objective: Fast-acting insulin analogs (FIA) have earlier and higher peak and shorter duration of action as compared with short-acting human insulin (SHI). Therefore, their pharmacokinetic profile would rather reflect glycemic profile after high-carbohydrate meal (HCM), whereas delayed and longer action of SHI would rather reflect glycemia after low-carbohydrate meal (LCM).Methods: In a cross-over, open label study we administered SHI (Gensulin R, Bioton) or FIA (Apidra, Sanofi), both in the same dose 15 minutes before high- and low-carbohydrate standard morning meal, in a random sequence during four days, in 30 insulin-treated persons with type 2 diabetes. Blood glucose was assessed before and every 30 minutes after meal.Results: In contrary to the expectation, there were no significant differences of glycemic profile after administration of SHI vs FIA after LCM as well as after HCM. However, median increments of glucose concentrations and measures of dispersion were lower after LCM, independently of administered insulin formulation (Fig.1).Conclusion: The results suggest that in persons with type 2 diabetes the composition of meal may be more important to achieve better postprandial glucose values and better glucose control than use of fast-acting insulin analog instead of short-acting human insulin.
M. Matalowski: Other Relationship; Zentiva Polska Sp. z o.o., Novo Nordisk. M.M. Lukawska-Tatarczuk: None. M. Hall: None. I.E. Towpik: Other Relationship; AstraZeneca, Novo Nordisk, Lilly Diabetes, Sanofi. Research Support; AstraZeneca. M. Masierek: Employee; BIOTON S.A. M. Walicka: Speaker’s Bureau; Sanofi, Eli Lilly and Company, Teva Pharmaceutical Industries. E. Franek: Speaker’s Bureau; Amgen Inc, AstraZeneca. Research Support; BIOTON. Speaker’s Bureau; Boehringer-Ingelheim, Merck Sharp & Dohme Corp, Sanofi.
Bioton SA
Source link
Leave a Reply